
    
      A 12-week randomized, double-blind, placebo-controlled trial to explore the effects of
      once-daily empagliflozin 10mg on hemodynamic parameters (pulmonary artery pressures) in
      patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic
      etiology) who already have a CardioMEMs device implanted for non-study related clinical
      reasons.
    
  